Application No. 10/645,312 Amendment dated February 16, 2006 After Allowance Under 37 C.F.R. 1.312 Docket No.: 58288(72021)

## **AMENDMENTS TO THE CLAIMS**

1. (Previously presented) A compound of the Formula:

or a pharmaceutically acceptable salt thereof, wherein:

G is oxygen or NH;

R<sub>X</sub> is straight or branched chain C<sub>1-8</sub>alkyl;

 $R_1$  and  $R_3$  are independently selected from hydrogen, cyano,  $C_{1-4}$ alkyl, halogen,  $C_1$ . <sub>2</sub>haloalkyl,

 $C_{1-2}$ haloalkoxy, mono- and di- $C_{1-4}$ alkylamíno,  $C_{1-4}$ alkoxy, and  $C_{1-4}$  alkylthio;  $R_5$  is hydrogen, halogen, hydroxy,  $C_{1-4}$ alkyl, or  $C_{1-4}$ alkoxy; K is N or CH;

R<sub>7</sub> is halogen, cyano, C<sub>1-4</sub>alkyl, C<sub>1-2</sub> haloalkyl, C<sub>1-2</sub>haloalkoxy, mono- and di-C<sub>1</sub>.

4alkylamino, C<sub>1-2</sub>alkoxyC<sub>1-4</sub>alkyl, C<sub>1-2</sub>alkoxycarbonyl, mono- and di-C<sub>1</sub>.

2alkylcarboxamido, -C(=O)NH<sub>2</sub>, hydroxyC<sub>1-2</sub>alkyl, trifluoromethylsulfonyl, 2,2,2-trifluoro-1-hydroxyethyl, or a 4-7 member heterocycloalkyl group containing 1 or 2 atoms independently chosen from N, O, and S;

R<sub>8</sub> is halogen, hydroxy, C<sub>1-2</sub>alkyl, C<sub>1-2</sub>alkoxy, or mono- and di-(C<sub>1-2</sub>alkyl)amino.

- 2. (Original) A compound or salt according to Claim 1 wherein  $R_1$  and  $R_3$  are not hydrogen.
  - 3-4. (Canceled).
- 5. (Original) A compound or salt according to Claim 1wherein G is NH and  $R_X$  is 1-ethyl propyl.

Docket No.: 58288(72021)

Application No. 10/645,312 Amendment dated February 16, 2006 After Allowance Under 37 C.F.R. 1.312

- 6. (Original) A compound or salt according to Claim 5 wherein  $R_1$  is cyano, methoxy, or methylthio and  $R_3$  is methyl or ethyl.
- 7. (Original) A compound or salt according to Claim 1 wherein G is oxygen and  $R_X$  is 1-ethylpropyl, 1-isopropyl-2-methypropyl, 1-propylbutyl, or 1-ethylbutyl.
- 8. (Original) A compound or salt according to Claim 7 wherein  $R_3$  is halogen,  $C_{1-2}$ alkyl, or methylamino.
- 9. (Original) A compound or salt according to Claim 7 wherein  $R_1$  is halogen, methyl, methoxy, ethyl, ethoxy, or  $C_{1-2}$ alkylamino.
- 10. (Original) A compound or salt according to Claim 7 wherein  $R_1$  is methylamino.
  - 11. (Cancelled).
- 12. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits a  $K_i$  value for CRF receptors of less than or equal to 1 micromolar.
- 13. (Original) A compound or salt according to Claim 1 wherein, in a standard in vitro CRF receptor binding assay the compound exhibits a K<sub>i</sub> value for CRF receptors of less than or equal to 100 nanomolar.
- 14. (Original) A compound or salt according to Claims 1 wherein, in a standard in vitro CRF receptor binding assay, the compound exhibits a K<sub>i</sub> value for CRF receptors of less than or equal to 10 nanomolar.

Application No. 10/645,312 Amendment dated February 16, 2006 After Allowance Under 37 C.F.R. 1.312 Docket No.: 58288(72021)

- 15. (Previously presented) A method for treating anxiety, or depression, comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound or salt according to Claim 1.
  - 16. (Canceled)
- 17. (Original) A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound or salt of Claim 1.
- 18. (Previously presented) A pharmaceutical composition according to Claim 17, wherein the composition is formulated as an injectable fluid, an aerosol, a cream, a gel, a tablet, a capsule, a syrup or a transdermal patch.
- 19. (Previously presented) A package comprising a pharmaceutical composition of Claim 17 in a container and further comprising indicia comprising at least one of:

instructions for using the composition to treat a patient suffering from anxiety, or instructions for using the composition to treat a patient suffering from depression.

20-26. (Canceled).